- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04923152
Effective Dose of Statin Post PCI
June 10, 2021 updated by: Javad Kojuri, Shiraz University of Medical Sciences
Effects of High- or Moderate-Dose Statin on 1-Year Major Adverse Cardiovascular Events (MACE) Post Percutaneous Coronary Interventions
In this study post coronary stenting patients, were enrolled to receive moderate dose versus high dose statin for 1 year, and the result of major adverse cardiovascular events were recorded
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
In this randomized double-blind clinical trial, the study population was all patients with a recent history of PCI who referred to the professor kojuri cardiovascular clinic for the first post-procedure visit.
In the first visit, patients were randomly divided into two groups Both groups were treated with Rosuvastatin 40 mg as high potency statin for one month after PCI.
In the first group, after one month, the statin level changed to Rosuvastatin 5 mg daily (moderate intensity).
In the second group, 40 mg of Rosuvastatin was continued for one year.
Then, the participants were evaluated in terms of MACEs, including any hospitalization due to acute coronary syndrome, as well as history of stroke and myocardial Infarction, subsequent unplanned revascularization and cardiac death.
The HS-CRP also checked between two groups
Study Type
Interventional
Enrollment (Actual)
582
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Outside Of The US
-
Shiraz, Outside Of The US, Iran, Islamic Republic of, 55318
- Professor kojuri cardiology clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
52 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- all patients who have undergone PCI due to chronic stable angina
Exclusion Criteria:
- Patients with acute coronary syndrome
- Primary LDL>190 mg/DL
- Patients who developed statin-induced myopathy or rhabdomyolysis
- Persistent increase in hepatic enzyme levels or hepatic failure
- Pregnancy and breast feeding
- Statin hypersensitivity
- Patients with history of multiple atherosclerotic events
- Patients who received high intensity statin before the study enrollment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: moderate dose statin
Patients 1 month post PCI, allocated to 5 mg rosuvastatin per day
|
5 mg rosuvastatin per day
|
Active Comparator: high dose statin
patients 1 month post PCI, allocated to 40 mg rosuvastatin
|
40 mg rosuvastatin per day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
major adverse cardiovascular events (MACE)
Time Frame: 1 year
|
major adverse cardiovascular events
|
1 year
|
serum level of HS-CRP
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2020
Primary Completion (Actual)
January 1, 2021
Study Completion (Actual)
April 1, 2021
Study Registration Dates
First Submitted
June 6, 2021
First Submitted That Met QC Criteria
June 10, 2021
First Posted (Actual)
June 11, 2021
Study Record Updates
Last Update Posted (Actual)
June 11, 2021
Last Update Submitted That Met QC Criteria
June 10, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IR.SUMS.MED.REC.1398.620
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
Dat available on demand of reviewer
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Statin Dose
-
Pepperdine UniversityRecruitingHigh Nitrate Dose | Moderate Nitrate Dose | Low Nitrate Dose | Nitrate-depleted DoseUnited States
-
Northumbria UniversityCompletedLow Fat Meal - Unadjusted Insulin Dose | High Fat Meal - Unadjusted Insulin Dose | High Fat Meal - Adjusted Insulin Dose +30 Percent | High Fat Meal - Adjusted Insulin Dose +Split Dose
-
University of Sao Paulo General HospitalCompletedStatin Adverse ReactionBrazil
-
Vestre Viken Hospital TrustOslo University Hospital; The Hospital of VestfoldCompletedStatin Adverse ReactionNorway
-
Vestre Viken Hospital TrustUniversity of Oslo; Oslo University Hospital; The Hospital of VestfoldCompleted
-
University of SaskatchewanMerck Frosst Canada Ltd.; Ministry of Health, SaskatchewanUnknownAdherence | Statin TherapyCanada
-
University of MelbourneNot yet recruiting10 Minute Mindfulness Meditation Practice Dose | 20 Minute Mindfulness Meditation Practice Dose | 30 Minute Mindfulness Meditation Practice Dose | 3-4 Minute Minimal Practice Dose
-
Insel Gruppe AG, University Hospital BernUniversity of BernRecruiting
-
Esperion Therapeutics, Inc.The Cleveland ClinicCompletedCardiovascular Diseases | Statin Adverse ReactionBelgium, Germany, United States, Austria, Estonia, Mexico, New Zealand, Spain, Russian Federation, Netherlands, Hungary, Australia, Denmark, South Africa, United Kingdom, Bulgaria, Argentina, Romania, Turkey, Croatia, Serbia, Canada, Lithuan... and more
-
Fujian Akeylink Biotechnology Co., Ltd.The First Hospital of Jilin UniversityRecruitingPharmacokinetics | Food Affect | Single Ascending Dose | Maximum Applicable DoseChina
Clinical Trials on moderate statin dose
-
University of Central FloridaAmerican College of Sports MedicineRecruiting
-
Yantai Yuhuangding HospitalRecruiting
-
University of MichiganNational Heart, Lung, and Blood Institute (NHLBI); University of Iowa; American... and other collaboratorsCompletedChildhood ObesityUnited States
-
Nathaniel JenkinsCompletedAcute Physiological Effects of Organic Guayusa ExtractUnited States
-
Yonsei UniversityNot yet recruitingHealthy Elderly Individuals With High LDL-cholesterol or Risk of Cardiovascular DiseaseKorea, Republic of
-
Yonsei UniversityUnknownDrug-eluting Stent (DES)Korea, Republic of
-
Seoul National University Bundang HospitalYuhan CorporationCompletedCardiovascular DiseasesKorea, Republic of
-
Arizona State UniversityNational Institutes of Health (NIH); National Center for Complementary and...Completed
-
Genentech, Inc.BioInvent International ABCompleted